Kura Oncology, Inc. (KURA) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a research report sent to investors on Saturday morning. They currently have $7.75 target price on the stock.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

A number of other brokerages have also weighed in on KURA. Cann restated a buy rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Monday, May 15th. Citigroup Inc. set a $13.00 price objective on Kura Oncology and gave the company a buy rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated an outperform rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Wednesday, June 28th. Cowen and Company began coverage on Kura Oncology in a report on Thursday, September 7th. They issued an outperform rating on the stock. Finally, Leerink Swann reiterated an outperform rating and set a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $14.15.

Shares of Kura Oncology (KURA) opened at 11.10 on Friday. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $13.80. The company has a 50-day moving average of $8.04 and a 200 day moving average of $8.77. The company’s market cap is $221.87 million.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. On average, analysts anticipate that Kura Oncology will post ($1.53) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Kura Oncology, Inc. (KURA) Raised to Buy at Zacks Investment Research” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/2887490/kura-oncology-inc-kura-raised-to-buy-at-zacks-investment-research.html.

Several large investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. increased its position in shares of Kura Oncology by 14.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after purchasing an additional 1,600 shares during the last quarter. Nationwide Fund Advisors grew its position in Kura Oncology by 66.2% in the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after acquiring an additional 10,258 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Kura Oncology in the 2nd quarter valued at about $102,000. Segantii Capital Management Ltd acquired a new position in Kura Oncology in the 1st quarter valued at about $120,000. Finally, Rhumbline Advisers acquired a new position in Kura Oncology in the 2nd quarter valued at about $131,000. 39.07% of the stock is owned by hedge funds and other institutional investors.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.